-
Xinlitai hypertension drug allisartan medoxomil and indapamide sustained-release tablets received clinical approval
Time of Update: 2021-06-17
Today, Xinlitai issued an announcement stating that the company received the "Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, and agreed to carry out clinical trials for allisartan medoxomil indapamide sustained-release tablets .
1-type antihypertensive drug Xin Litan (alisartan medoxomil tablets) to cover different market segments .
-
Deepen the reform of public hospitals and promote the improvement of the medical service capabilities of primary hospitals
Time of Update: 2021-06-17
In response to the national health care reform "strong grassroots" policy call, national health Health Management Institute under the National Health Committee of Hospital Health Committee of Medical Administration Authority Instructions, Hui cause support, five years continued to carry out a "set sail in the county" - County-level public hospital hospital management and clinical key specialty capacity building project .
-
The per capita financial subsidy standard for resident medical insurance is not less than 580 yuan per person per year
Time of Update: 2021-06-17
The "Notice" proposes to promote the reform of medical insurance payment methods, normalize the centralized procurement of drugs , strengthen the supervision of medical insurance funds, and continuously improve the efficiency of the use of residents' medical insurance funds .
-
Multi-departmental support for favorable policies frequently raises concerns about children's medication problems
Time of Update: 2021-06-17
(Zhan Ni, Public Opinion Monitoring Center of China Health Media Group) Medical Network News, June 9th, for a long time, the supply of special medicines for children has not been able to meet the clinical needs.
-
The price is down and the effect remains the same!
Time of Update: 2021-06-17
Zhang Lan, Director of the Department of Pharmacy, Xuanwu Hospital, Capital Medical University: Compared with the original drugs in the 14 centralized procurements we evaluated, there was no significant difference (statistical difference) in clinical effects and use (statistical differences), for example, in the treatment of virality.
-
Where is the way out for Guocai to accelerate the implementation of generic chemical companies?
Time of Update: 2021-06-17
Figure 4: The number of generic drugs and the relative price ratio of original research drugsSource: FDA, IMSThe first generic drugs of domestic high-quality generic drug companies have a good market competition pattern .
-
Difficulty in registering and setting up files in obstetrics departments of many top three general hospitals in Beijing
Time of Update: 2021-06-17
Although the source tension has eased It is still difficult to register on the same day On May 15th, the reporter also logged on to the unified platform for appointment registration in Beijing to check the registration status of the Grade-A general hospital near Xiao Zhen's home .
-
National Health Commission: Establish an expert group to promote the construction of a hierarchical diagnosis and treatment and medical consortium
Time of Update: 2021-06-17
On June 7, the National Health and Health Commission issued a notice on the establishment of an expert group to promote the construction of hierarchical diagnosis and treatment and medical consortium, to carry out evaluation and supervision of the implementation of the national graded diagnosis and treatment and medical consortium construction .
-
Shanghai Pharmaceuticals duloxetine hydrochloride enteric-coated tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-06-17
(hereinafter referred to as “Shanghai Pharmaceuticals Zhongxi”) has received the relevant duloxetine hydrochloride enteric-coated tablets issued by the State Food and Drug Administration.
In January 2020, Shanghai Pharmaceuticals Zhongxi submitted an application to the State Food and Drug Administration for the consistency evaluation of the generic drug and was accepted .
-
Nature Reveals the "Dormancy" Mechanism of Tumor Cells Effectively Prevents Metastatic Cancer
Time of Update: 2021-06-17
Gene expression of natural killer cells in dormant and metastatic states, and the distribution of interferon-γIn addition to studying the mechanism of tumor dormancy, the researchers also studied the process of tumor cells from dormancy to activation, and they found clues in the tumor metastasis group .
-
Hengrui, Hausen... Great Harvest Won 24 New Anti-tumor Class 1 Drugs
Time of Update: 2021-06-17
The first domestically-made ADC drug was born, and 24 domestically-made anti-tumor Class 1 new drugs have been approved On June 9, the State Food and Drug Administration approved the listing of Rongchang Biologic’s vedicitumumab for injection, becoming the first domestic antibody-drug conjugate (ADC) in China, suitable for those who have received at least 2 types of systemic chemotherapy HER2 overexpression in patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) .
-
The State Food and Drug Administration issued an announcement on the cancellation of the medical device registration certificate
Time of Update: 2021-06-17
Medical Network News, June 10, June 9th, the State Food and Drug Administration issued an announcement, in accordance with the "Medical Device Registration Management Measures", according to the enterprise application, the registration number of Nikon Corporation is now cancelled: National Machinery Injection 20172226595, Product name: Medical device registration certificate for biological microscope .
-
Affected by Pfizer Xeljanz, Incyte's Jakafi review application was delayed by the FDA for 3 months
Time of Update: 2021-06-17
Incyte said on Tuesday that the FDA has postponed the approval date of the regulatory application for Jakafi for the treatment of steroid-refractory chronic graft-versus-host disease (GVHD) by 3 months.
-
New indications for BeiGene Zebutinib Capsules are about to be approved
Time of Update: 2021-06-17
On June 7, the official website of the State Food and Drug Administration showed that BeiGene Zebutinib Capsule's new adaptation marketing application (acceptance number CXHS2000037) was in the "under review" stage and will be approved by the NMPA in the near future .
-
Liu Guochang, independent director of Boji Pharmaceuticals, resigns after his term of office expires
Time of Update: 2021-06-17
Liu Guochang has served as an independent director in the company for six years.
Liu Guochang will no longer hold any position in the company after the resignation report takes effect .
-
Beware of the impact of drug price linkage before mass purchase!
Time of Update: 2021-06-17
The most likely reason is that the volume purchase prices of various regions from last year to the present have been collected by the country's volume purchases, resulting in a low price limit .
-
Hawthorn market has fallen, and Honghe Fujie lotion has a high gross profit!
Time of Update: 2021-06-17
5. Analysis of main demand products and enterprises Table 1: Photographs of Chinese patent medicines and manufacturers with high demand for hawthorn raw materials In terms of proprietary Chinese medicines, according to statistics from the Big Data Platform of the Pharmaceutical Industry of Tiandi Yuntu, 163 Chinese patent medicines currently on the market contain hawthorn .
-
Pfizer pneumococcal 20-valent conjugate vaccine approved by the U.S. FDA
Time of Update: 2021-06-17
The press release stated that this is the first approved vaccine against 20 pneumococcal serotypes that cause most aggressive diseases and pneumonia, including 7 serotypes that cause 40% of pneumococcal disease cases and deaths in the United States .
-
Execution of 23 large varieties with quantity procurement results
Time of Update: 2021-06-17
On May 17, the Ningxia Medical Security Bureau issued the "Notice of the Public Resource Exchange Administration of the Health and Health Commission of the Ningxia Hui Autonomous Region Medical Insurance Bureau on the implementation of the first batch of inter-provincial alliance drug centralized procurement results", showing that the selected varieties are 12, 10 of which are injections .
-
The adjustment of the medical insurance catalogue starts! 4 drugs are planned to be added, and new drugs approved before June 30 can be declared!
Time of Update: 2021-06-17
In the expert review stage, the National Medical Insurance Bureau will demonstrate the expert opinions of the professional group, and finally determine the list of drugs in five aspects: direct transfer, negotiation transfer, direct transfer, can transfer, and adjust the limited payment scope .
